PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010083141) BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

What is claimed is:

1. A compound of Formula (I)


(I), or a pharmaceutically acceptable salt thereof, wherein

A is a five- or six-membered heteroaromatic ring containing from one to three heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaromatic ring is optionally substituted with one or two groups selected from halo, haloCi-galkyl, hydroxy, amino, Cμ6alkoxy, and Cμgalkyl;

B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from Cμ^alkoxy, Ci^alkyl, Ci-3alkylamino-Ci-6alkoxy, cyano, C^dialkylamino-C1-6alkoxy, halo, haloCf^alkoxy, haloCμgalkyl, hydroxy, methylamino, and amino; D is selected from


wherein " ^ " denotes the point of attachment to the nitrogen atom of the parent

molecule and " ^ " denotes the point of attachment to the Ε' moiety; Ra is selected from hydrogen, C1-6 alkyl, Cμ6 alkoxy, hydroxy.

dimethylamino, amino, methylamino and benzyl ami no, wherein the phenyl part of the benzyl is optionally substituted with one, two, or three substituents independently selected from Cχ.6 alkyl,
each R is independently selected from hydrogen, Cj-6 alkoxy, Chalky!,

C^alkylamino, amino, Ci-edialkylamino, halo, hydroxy; and


wherein n is 0 or 1 and " > " denotes the point of attachment to the ring; Rz is Ci-6alkyl; and E is selected from C^alkyl, C^cycloalkyl, benzyl, phenyl, and a five- to six-membered heteroaromatic ring containing one or two nitrogen atoms, wherein the phenyl, the phenyl part of the benzyl, and the heteroaromatic ring are each optionally substituted with one, two, or three substituents independently selected from Ci- 6alkoxy, C1-6 alkyl, C[-6alkylsulfonyl, cyano, halo, haloQ-ealkoxy, haloCi. ealkylsulfonyl, haloCi-ealkyl, and a five-membered heteroaromatic ring containing one, two, or three nitrogen atoms, wherein the hetoeraromatic ring is optionally substituted with one C1-S alkyl group.

2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is selected from imidazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, pyridazinyl, pyridinyl, and triazolyl; wherein each is optionally substituted with one group selected from halo, haloCi-ealkyl, and Ci-galkyl.

3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from Ci^alkoxy, cyano, and halo.

4. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein D is selected from
and


wherein " ^ " denotes the point of attachment to the nitrogen atom of the parent

molecule and " ^ " denotes the point of attachment to the 'E' moiety;

Ra is selected from hydrogen, C1^ alkyl, hydroxy, amino and benzylamino, wherein the phenyl part of the benzyl is optionally substituted with one halo group; each Rb is independently selected from hydrogen, C1-6 alkoxy, Q-ealkyl,

Ci_6alkylamino, amino, Ci-gdialkylamino, halo, hydroxy; and


wherein n is 0 or 1 and " > " denotes the point of attachment to the ring; and

Rz is Ci-βalkyl.

5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein E is selected from C^alkyl, benzyl, phenyl, pyrazolyl, pyridinyl, wherein the phenyl, the phenyl part of the benzyl, the pyrazolyl, and the pyridinyl are each optionally substituted with one, two, or three substituents independently selected from Ci-galkoxy, Ci-6alkylsulfonyl, cyano, halo, haloC^alkoxy, haloCμgalkylsulfonyl, imidazolyl, pyrazolyl, and triazolyl, wherein the imidazolyl, pyrazolyl, and triazolyl rings are optionally substituted with one C1-6 alkyl group.

6. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is selected from imidazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, pyridazinyl, pyridinyl, and triazolyl; wherein each is optionally substituted with one group selected from halo, haloCμgalkyl, and Cj-galkyl. B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from Cj-salkoxy, cyano, and halo; D is selected from


and


wherein " ^ " denotes the point of attachment to the nitrogen atom of the parent

molecule and " ^ " denotes the point of attachment to the 'E' moiety; Ra is selected from hydrogen, Ci-6 alkyl, hydroxy, amino and benzylamino, wherein the phenyl part of the benzyl is optionally substituted with one halo group; each Rb is independently selected from hydrogen, C1-6 alkoxy, Cnsalkyl, Ci-ealkylamino, amino, Cμsdialkylamino, halo, hydroxy; and

wherein n is 0 or 1 and " ^ " denotes the point of attachment to the ring;

Rz is Ci-6alkyl; and

E is selected from
benzyl, phenyl, pyrazolyl, pyridinyl, wherein the phenyl, the phenyl part of the benzyl, the pyrazolyl, and the pyridinyl are each optionally substituted with one, two, or three substituents independently selected from C^alkoxy, C^alkylsulfonyl, cyano, halo, haloCi.galkoxy,
imidazolyl, pyrazolyl, and triazolyl, wherein the imidazolyl, pyrazolyl, and triazolyl rings are optionally substituted with one C1.6 alkyl group.

7. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

A is selected from imidazolyl and triazolyl; wherein each is optionally substituted with one group selected from halo and
B is selected from phenyl and pyridmyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from
cyano, and halo;

D is selected from


wherein " ^ " denotes the point of attachment to the nitrogen atom of the parent

molecule and " ^ " denotes the point of attachment to the 'E' moiety;

Ra is selected from hydrogen and Cj-6 alkyl; each Rb is independently selected from hydrogen, Ci-6 alkoxy, Ci-ealkyl, amino, C^alkylamino, C1-6dialkylamino, halo, hydroxy;

E is selected from phenyl, pyridyl, and pyrazole, wherein the phenyl and the heteroaromatic ring are each optionally substituted with one, two, or three substituents independently selected from Cj-6 alkyl, Cj-ealkoxy, cyano, halo, haloCi.galkoxy.

8. A compound of Formula (I)


(D, or a pharmaceutically acceptable salt thereof, wherein A is a five- or six-membered heteroaromatic ring containing from one to three heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaromatic ring is optionally substituted with one or two groups selected from halo, haloCi-βalkyl, hydroxy, amino, C^alkoxy, and Ci-6alkyl;

B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from
C1-6alkyl, Ci.3alkylamino-Ci-6alkoxy} cyano, C1-3dialkylamino-Q..6alkoxy, halo, haloCj-ealkoxy, haloCi.galkyl, hydroxy, methylamino, and amino; D is selected from


wherein " ^ " denotes the point of attachment to the nitrogen atom of the parent molecule;

" -^ " denotes the point of attachment to the 'E' moiety; Ra is selected from hydrogen, C1-6 alkyl, Ci-6 alkoxy, hydroxy, dimethylamino, amino, methylamino and benzylamino, wherein the phenyl part of the benzyl is optionally substituted with one, two, or three substituents independently selected from Ci-6 alkyl, Q-galkoxy, cyano, halo, haloCi.galkoxy, and haloC1-6alkyl;

Rb is selected from hydrogen, Ci-ealkylamino, amino, C1-6dialkylamino, halo, and hydroxy; and

E is selected from Ci^alkyl, C4-6Cy cloalkyl, benzyl, phenyl, and a five- to six-membered heteroaromatic ring containing one or two nitrogen atoms, wherein the phenyl, the phenyl part of the benzyl, and the heteroaromatic ring are each optionally substituted with one, two, or three substituents independently selected from C1^ alkyl, Ci-6alkoxy, cyano, halo, haloCi-ealkoxy, and halo Cj.6alkyl.

9. A compound selected from:

(Z)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-8,9-dihydro-5H-[l ,2,4]tπazolo[l ,5-a]azepin-2-amine; (S,Z)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-8,9-dihydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine;

(R,Z)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-8,9-dihydro-5H-[l,2,4]triazolo[lJ5-a]azepin-2-amine;

(Z)-9-(4-fluorophenyl)-N-(3-methoxy-4-(3-methyl-lH-l,2,4-triazoI-l-yl)phenyl)-8s9-dihydro-5H-[l,2}4]triazolo[l,5-a]azepin-2-amine;

(S,Z)-9-(4-fluorophenyl)-N-(3 -methoxy-4-(3 -methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-8,9-dihydro-5H-[l ,2,4]triazolo[l ,5-a]azepiii-2-amine;

(R,Z)-9-(4-fluorophenyl)-N-(3 -methoxy-4-(3 -methyl- IH-1 ,2,4-triazol- 1 -yl)phenyl)-8,9-dihydro-5H-[l)2,4]triazolo[l,5-a]azepin-2-amine; 9-(4-fluoroρhenyl)-N-(3-methoxy-4-(3-methyl-lH-l;254-triazol-l-yl)phenyl)- 6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[lj5-a]azepin-2-amine 2,2,2-trifiuoroacetate;

(Z)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(2,4-dichlorophenyl)-8,9-dihydro-5H-[l ,2,4]triazolo[ 1 ,5-a]azepin-2-amine;

(Z)-N-(4-(4-chloro- 1 H-imidazol-1 -yl)-3-methoxyphenyl)-9,9-dimethyl-8,9-dihydro-5H-[l,2,4]triazolo[l ,5-a]azepin-2-amine 2,2,2-trifluoroacetate;

N~(4-(4~chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorophenyI)-5,6,7,8-tetrahydro-[l ,2,4]triazolo[l ,5-a]pyridin-2-amine 2,2,2-irifiuoroacetate;

2-(4-chloro-lH-imidazol-l-yl)-5-(8-(4-fluorophenyl)-5,6,7s8-tetrahydro-[1 ,2,4]triazolo[l ,5-a3pyridin-2-ylamino)benzonitrile 2,2,2-trifluoroacetate;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(2,4-dichlorophenyl)-5,6,7,8-tetrahydro-[l,2f4]triazolo[l,5-a]pyridin-2-amine ; N-(3-fluoro-4-(5-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-8-(4-fluorophenyl)- 5,6,7,8-tetrahydro-[l ,2,4]lriazolo[l ,5-a]pyridin-2-amine;

(S)-N-(3-fluoro-4-(5-methyl-l H-1 ,2,4-triazol- 1 -yl)phenyl)-8-(4-fluorophenyl)~5,6,7,8-tetrahydro-[ 152s4]triazolo[l s5-a]pyridm-2-amine;

(R)-N-(3-fluoro-4-(5-methyl-lH-l,2}4-triazol-l-yl)phenyl)-8-(4-lluorophenyl)-5,6,7,8-tetrahydrθ"[l,2,4]triazolo[lf5~a]pyridin-2-amine;

N~(4-(4-Chloro~lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H-tl ,2j4]triazolo[l ,5-a]azepm-2-amine;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-6,758,9-tetrahydro-5H-[ls2,4]triazolo[l,5-a]azepin-2-amine; (R)-N-(4-(4-cliloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)- 6,7?8,9-tetrahydro-5H~[l f2,4]triazolo[ 1 ,5-a]azepin-2-amine;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(2,4-dichlorophenyl)-6J,8,9-tetrahydro-5H-[l,2,4]1xiaz»lo[l,5-a]azepitt-2-amine 2,2!)2-trifluoroacetate;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(2,4-dichlorophenyl)-6,7,8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro- 1 H-imidazol-1 -yl)-3-methoxyphenyl)-9-(2,4-dichlorophenyl)-6 ,7,8, 9-tetrahydro- 5 H-[1 ,2,4] triazolo [ 1 ,5 -a] azepin-2-amine ;

N-(4-(4-chloro- 1 H-Imidazol- 1 -yl)-3 -methoxyphenyl)-9-(3 ,4-difluorophenyl)-6,7,8,9-tetrahydro-5H-[l 52,4]triazolo[ 1 ,5-a]azepin-2-amine 2,2,2-trifluoroacetate; (S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3f4-difluorophenyl)-6,7,8,9-tetrahydro-5H-[ls2,4]triazolotl,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3,4-difluorophenyl)-6 , 7,8 , 9-tetrahydro-5 H- [ 1 ,2 ,4] triazolo [ 1 , 5 -a] azepin-2-amine ;

N-(3 -fluoro-4-(3 -methyl- 1 H- 1 ,2,4-triazol- 1 -yl)pheny l)-9-(4-fiuoropheny I)-6,7,8,9~tetrahydro-5H~[l,2,4]tπazolo[l,5~a]azepin-2-amine;

(S)-N-(3 -fluoro-4-(3 -methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H-tl,2,4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(3-fluoro-4-(3-methyl- 1 H- 1 ,2,4-triazol- l-yl)phenyl)-9-(4-fluorophenyl)-ό,7 ,8 ,9-tetrahydro- 5 H- [ 1 ,2 ,4] triazo Io [ 1 , 5 -a] azepin-2~amine;

N-(2-fluoro-5-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)~9-(4-fluorophenyl)-6,7,8j9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-ainine 2,2,2-trifluoroacetate;

(S)-N-(2-fluoro-5-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-9-(4-fluorophenyl)-6,7,8,9-telrahydro-5H-[l,2,4]triazolo[l,5-a]azepiii"2-aniine;

(R)-N-(2-fluoro-5-methoxy-4-(3-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)ρhenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2~amine; N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3 -methoxyρhenyl)-9 -(4- (trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[ 1 ,5-a]azepin~2~ amine 2,2,2-trifluoroacetale;

N-(4-(4-chloro- lH~imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-chloroρhenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[lJ5-a]azepin-2-amine 2,2,2-trifluoroacetate; N-(4-(3-chloro~lH-l>2,4-triazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)- 6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-2-amine 2,2,2-trifluoroacetate; 9-(4-chlorophenyl)-N-(3-methoxy-4-(l-methyl-lH-pyrazol-4-yl)phenyl)-6,7,8,9-tetrahydro-5H-[ 1 ?2,4]triazolof 1 ,5-a]azepin-2-amine 2,2,2-trifluoroacetate;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(2,4-difluorophenyl)-6,7f8,9-tetrahydro-5H-[l ,2,4]triazolo[ 1 ,5-a]azepin-2-amine 2,2,2-trifluoroacetate;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(2,4-difluorophenyl)-6 ,7,8 , 9-tetrahy dro- 5 H-[ 1 ,2 ,4]tr iazolo [ 1 , 5 -a] azepin-2-amine ;

(R)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyρhenyl)-9-(2,4-difluoropheny l)-6,7 , 8 ,9-tetrahy dro-5 H- [ 1 ,2 ,4] triazo Io [ 1 , 5 -a] azepin-2 -amine ; N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3,5-difiuorophenyl)- 6,7,8,9-tetrahydro-5H-[ 1 ,2?4]triazolo[ 1 ,5-a]azepin-2-amine;

(S)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(3 ,5 -difluorophenyl)-6,7,8,9-tetrahydro-5H-[lJ2,4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyρhenyl)-9-(3 ,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5 -a] azepin-2-amine;

N-(4-(4-chloro- 1 H- imidazol- 1 -y I)-3 -methoxyphenyl)-9-(6-chloropyridin-3 -yO-6,7,8 ,9-letrahydro-5H-[ 1 ,2,4]triazolo[ 1 ,5-a] azepin-2-amine 2,2,2-trifluoroacetate;

N-(4-(4-chloro- lH-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-chloro- 1 H-pyrazol-l-yl)-6,7,8,9-tetrahydro-5H-[l,2;4]triazolo[l;5-a]azepin-2-amine 2,2,2-trifluoroacetate;

N-(4-(4-(difluoromeihyl)- 1 H-imidazol- 1 -yl)-3 -methoxyphenyl)-9-(4-fluorophenyl)-6,73,94etrahydro-5H-[l,2,4]1ria-rølo[l>5-a]a-^in-2-ainine 2,2,2-trifluoroacetate;

N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(3-fluorophenyl)-6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-2-amine;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3-fluorophenyl)-6,7,859-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(R) -N-(4-(4 -chloro - 1 H-imidazol- 1 -yl)-3 -methoxyphenyl)-9-(3 -fluorophenyl)-6,7,8,9-tetrahydro-5H-[l,2j4]triazolo[l,5-a]azepin-2-amine;

9-(4-fluorophenyI)-N-(3-melhoxy-4-(6-methylρyridazin-4-yl)phenyl)-6,7}8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine; N-(4-(4 -chloro- 1 H-imidazol- 1 -yl)-3 ,5-difluorophenyl)-9-(4-fluorophenyl)- 6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-fluoro-5-methoxyphenyl)-9-(4-fluorophenyl)-6,7>8}9-tetrahydro-5H-[l52,4]triazolo[l,5-a]azepin-2-amine;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3,4,5-trifluorophenyl)-6J7,8J9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3,4,5-trifluorophenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3,4!5-trifluoroρhenyl)-6,7,8,9-tetrahydro-5H-[ 1 S2,4]triazolo[l ,5-a]azepin-2-amine; N-(4-(4-chioro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3-chlorophenyl)- 6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(4- (4- chloro- 1 H-imidazol- 1 -yl)-3 -methoxypheny 1) -9-(3 -chlorophenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro-lH-imidazol-l-yI)-3-methoxyphenyl)-9-(3-chlorophenyl)-6J7,8,9-tetrahydro-5H-[lJ2,4]triazolo[lJ5-a]azepin-2-amine;

N-(4-(4-chIoro- 1 H-imidazol- 1 -y I)- 3 -methoxyphenyl)-9-(2-fluoroρhenyl) -6,7,8, 9-tetr ahydro-5H-[l ,254]triazolo[l ,5-a]azepin-2-amine;

4-(2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a)azepin-9-yl)benzonitπle

(S)-N-(4-(4-chloro-l H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(2-fluorophenyl)-6,7,8,9-tetrahydro-SH-fl^^JtriazoloJl^-alazepin^-amine; (R)-N-(4-(4-chloro- 1 H-imidazol-1 -yl)-3-methoxyphenyl)-9-(2-fluorophenyl)- 6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

9-(4-fluoiOphenyl)-N~(3-methoxy-4-(3-methyl-l,2,4-oxadiazol-5-yl)phenyl)-6,7,8, 9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-2-amine;

9-(4-fluorophenyl)-N-(3-methoxy-4-(3-methylisoxazol-5-yl)phenyl)-6,758,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine; fe/-(6R,9S)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyρhenylamino)-9-(4-fluorophenyl)-657s8?9-tetrahydro-5H-[l ,2s4]triazolo[l s5-a]azepin-6-ol 2,2,2-trifluoroacetate; re/-(6S,7Rf9R)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-9-(4-fluorophenyl)-6;7,8;9-tetrahydro-5H-[l52,4]triazolotl,5-a]azepine-6,7-diol 2,2,2-trifluoroacetate; re/~(6S,7R,9S)-2-(4-(4-chloro-l H-imidazol- 1 -yl)~3-methoxyplienylamino)-9-(4-fluorophenyl)-6,7J8,9-tetrahydro-5H-[l ,2,4]triazolo[ 1 ,5-a]azepine-6,7-diol 2,2,2-trifluoroacetate; re/-(6R,9R)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-9-(4-fluorophenyI)-6,7,8,9-tetrahydro-5H-[ls2}4]triazolo[l}5-a]azepin-6-ol 2,2,2-trifluoroacetate; re/-(7S,9R)-2-(4-(4-chloro-lH-imidazol-l~yl)-3-methoxyphenylamino)-9-(4-fluoroρhenyl)-6Js8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-7-ol 2,2,2-trifluoroacetate;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(3,4,5-trifluorophenyl)-6 ,7,8, 9-tetrahydro-5 H-[ 1 ,2,4] triazolo [ 1 , 5 -a] azepin-2-amine;

(S)-N-(4-(3-chloro-lH-l,2f4-triazol-l-yl)-3-methoxyρhenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[ 1 ,5-a]azepin-2-amine; (R)-N-(4-(3-chloro-lH-l ,2,4-triazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-5-(4-jEluorophenyl)- 5,6,7,8-tetrahydro-[l ,2,4]triazolo[l ,5-a]pyridin-2-amine 2,2,2-trifluoroacetate;

N-(4-(4-chloro- lH-imidazol- 1 -yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyridin-2-amine; r^(6S,7R,9S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-6,7-difluoro-9-(4-fluorophenyl)-6,7?8s9-tetrahydro-5H-[l,254]lriazolotl,5-a]azepin-2-amine 2,2,2-trifluoroacelate; and

2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-9-(4-fluorophenyl)-6f7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepm-9-oϊ;

N-(3-fluoro-4-(5 -methyl- 1 H-1 ,2,4-triazol-l -yl)phenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-2-amme; (S)-N-(3-fluoro-4-(5-methyl-lH-l ,2,4-triazol-l -yl)phenyl)-9-(4-fluorophenyl)-6,758,9-tetrahydro-5H-[l,2J4]triazolo[l55-a]azepin-2-amine;

(R)-N-(3-fluoro-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-9-(4-fluorophenyl)-6,7s8,9-tetrahydro-5H-[l,2;4]triazolo[l,5-a]azepin-2-amine;

N-(3-fluoro-4-(3-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7ϊ8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(3-fluoro-4-(3-methyl-lH-l,2!4-lriazol-l-yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l!5-a]azepin-2-amine; (R)-N-(3-fluoro-4-(3-methyHH-l,2,4~triazol-l-yl)phenyl)-9-(4- (trifluoromethoxy)phenyl)-6,7,8;9-tetrahydro~5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

N-(3-fluoro~4-(5 -methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azeρin-2-amine;

(S)-N-(3-fluoro-4-(5-methyl-lH-l,2,4~triazol-l~yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7,8s9-tetrahydro-5H-[l,2,4]triazolo[l;5-a]azepin-2-amine;

(R)-N-(3-fluoro-4-(5-methyl-lH-l,254-triazol-l-yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6s7,8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azeρin-2-aiΗine;

N-(4-(4-chIoro- 1 H-imidazol- 1 -yl)-3 -methoxyphenyl)-9-(4-isopropoxyphenyl)-6,7,859-tetrahydro-5H-[ls2j4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-isopropoxyphenyl)-6,75859-tetrahydro-5H-[l,2,4]tnazolo[l,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-isopropoxyphenyl)-6,7J8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-aiΗine; N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,7J8,9-tetrahydro-5H-[l>2,4]triazolo[ls5-a]azepin-2-amine;

(S)-N-(4-(4-chloro-l H-imidazol- l-yl)-3-methoxyphenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6J7,8,9-tetrahydro-5H-[l,2!4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6;7,8;9-tetraliydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-2-amine;

N-(3,5-difluoro-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,758,9-tetrahydro-5H-[l,2,4]triazolo[l,5"a]azepm-2-amine;

9-(4-(2,2-difluoroethoxy)phenyl)-N-(4-(3 , 5 -dimethyl- 1 H- 1 ,2,4-triazol- 1 -yl)-S-fluorophenyO-βJ.δ^-tetrahydro-SH-fl^^ltriazolotl^-ajazepin^-amine 2,2,2-trifluoroacetate;

N-(3-fluoro-4-(5-methyl-l H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(252J2-trifluoroethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,2?4]triazolo[lf5-a]azepin-2-amine;

(S)-N-(3-fluoro-4-(5-methyl-l H- 152s4-triazol- 1 -yl)phenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,7?8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5-a]azepin-2-amine;

(R)-N-(3-fluoro-4-(5-metJiyl-lH-l,2,4-triazoH-yl)phenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,75859-tetrahydro-5H-[l,2,4]tπazolo[l,5-a]azeρm-2-amine;

N-(3-fluoro-4-(3-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine; (S)-N-(3-fluoro-4-(3-methyl- IH- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,7s8s9-tetrahydro-5H-[l52!4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(3-fluoro-4-(3-methyl- IH- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,7,8,9-tetrahydro-5H~[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine;

N-(2-fluoro~5~methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-9-(4-(2,2,2-trifluoroetlioxy)phenyl)-6,7>8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(2-fluoro-5-melhoxy-4-(3-methyl-lH-l,2f4-triazol-l-yl)phenyl)-9-(4-(2,2,2-trifluoroethoxy)phenyl)-6,7}8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine;

(R)-N-(2-fluoro-5-methoxy-4-(3-methyl- 1 H-1 ,2,4-triazol-l -yl)phenyI)-9-(4-(252,2-trifluoroethoxy)phenyl)-657,8,9-tetrahydro-5H-[l5254]triazolo[l,5-a]azepin-2-amine;

9-(4-(2,2-difluoroethoxy)phenyl)-N-(3-fluoro-4-(5-methyl-lH-l,2J4-triazol-l-yl)phenyl)-6,7;8,9-telrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(S)-9-(4-(2,2-difluoroethoxy)phenyl)"N-(3-fluoro-4-(5-methyl-lH-lJ2s4-lriazol-l-yl)phenyl)-6,7,8f9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepIn-2-amine;

(R)-9-(4-(2,2-difluoroethoxy)phenyl)-N-(3-fluoro-4~(5-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-6,7,8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine;

N-(3-fluoro-4-(3-methyl-l H-l,2?4-triazol-l -yl)phenyl)-8-(4-(trifluoromethoxy)phenyl)-5,6,7J8-tetrahydro-[l,2J4]triazoIo[l,5-a]pyridin-2-amine; (S)-N-(3-fluoro-4-(3-methyl-lH-l ,2)4-triazol-l-yl)phenyl)-8-(4- (trifluoromethoxy)phenyl)-5?6,7f8-tetrahydro-[l,2,4]triazolo[l,5-a]pyridin-2-amine;

(R)-N-(3 -fluoro-4-(3-methyl- 1 H- 1 ,2, 4-triazol- 1 -yl)phenyl)-8-(4-(trifluoromethoxy)phenyl)-5,6,7,8-tetrahydro-[l ,2,4]triazolo[ 1 ,5-a]pyridin-2~amine;

(S)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[ 1 ,5-a]azepin-2-amine;

(R)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3 -methoxyphenyl)-9-(4-(trifluoromethoxy)phenyl)-6J7,8,9-tetrahydro-5H-[l,2;4]triazolo[l,5-a]azepin-2-amine; 9-(4-(difluoromethoxy)phenyl)-N-(3-methoxy-4-(3-methyHH-l52,4-triazol-l-yl)phenyl)-6?7,8f9-tetrahydro-5H-[l,2,4]triazolo[l55-a]azepin-2-amine;

9-(4-(difluoromethoxy)phenyl)-N-(3-methoxy-4-( 3 -methyl- IH-1, 2,4-triazol-l-yl)phenyl)-6,7,8,9-tetrahydro-5H-[l,2f4]triazolo[l,5-a]azepin-2-amine;

N-(3 -methoxy-4-(3-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(methylsulfonyl)phenyl)-6,7,8,9-tetrahydro-5H-[l ,2,4]triazolo[ 1 ,5-a]azepin-2-amine;

N-(3 -methoxy-4 -(3 -methyl- 1 H- 1 ,2,4-triazoI- 1 -y l)ρhenyl)-9-(4-(trifluoromethylsulfonyl)phenyl)-6,7,8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine;

N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-metlioxyphenyl)-9-(4-ethoxypheriyl)-6,7,8,9-teti-ahydro-5H-[l,2}4]triazolo[l,5»a]azepin-2-amine;

9-(4-ethoxyphenyl)-N-(3-methoxy-4-(3-methyl-lH4,2;4-triazol-l-yl)phenyl)-6 J,8,9-tetrahydro-5H-[l ,2,4]triazolo[l ,5~a]azepin-2-amine; N-(4-(4-chloro~lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-7-methylene-6,7,859-tetrahydro~5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-melhoxyphenyl)-9-(4-lluoroplienyl)-7-methylene-6s75859-teirahydro~5H-[ 1 ,2,4]triazolo[ 1 ?5~a]azeρin-2-amine;

(R)-N-(4-(4-chloro-lH-imidazol~l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)~ 7-metfaylene-6}7s8}9-tetrahydro-5H-[ 1 ,2,4]triazolo[ 1 ,5-a]azepin-2-amine;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-7-methyl-6J7,8?9-tetrahydro-5H-[l52,4]triazolo[l,5-a]azepin-2-amine;

2-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenylamino)-9-(4-fluorophenyl)-8,9-dihydro-5H-[lf2,4]triazoIo[l,5-a]azepin-7(6H)-one; 2-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenylamino)-9-(4-fluorophenyl)-8,9-dihydro-5H-[l,2,4]triazolo[l,5-a]azepin-7(6H)-one O-methyl oxime;

N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-7,7-difluoro-9-(4-fluorophenyl)-6s7,859-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-2-amine; N2-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4~fluorophenyl)- N7-methyl-6,7;8,9-tetrahydro-5H-[l,254]triazolo[l,5-a]azepine-257-diamine;

N2-(4-(4-chloro - 1 H-imidazol - 1 -y I)-3 ~methoxyphenyl)-9-(4-fluoroρhenyl)-N7,N7~dimethyl-6,758,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepine-2}7-diamine;

7-(azelidin- 1 -yl)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-6,7,8,9-tetrahydro~5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-fluorophenyl)~7-(pyrrolidin-l-yl)-6J7,8J9-letrahydro-5H-[l,2,4]triazolo[l,5-a]azeρm-2-amine;

N-(4-(4-chloro- lH-imidazol- 1 -yl)~3-methoxyphenyl)-9-(4-fluorophenyl)-5,6,8,9-tetxahydrosρiro[[lJ2,4]triazolo[l,5-a]azepme-7J2'-[lf3]dioxolan]-2-amine; N-(4-(4-chIoro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-7,7~ dimelhoxy-6,7s8,9-tetrahydro-5H-[l,2J4]triazolo[l,5-a]azepin-2-amine;

2-(4-(4-chloro- 1 H-imidazol- 1 -y I)-3 -methoxypheny lamino)-7 -ethyl-9- (4-fluorophenyl)-6,7,8!9-tetrahydro-5H-[l;2,4]triazolo[l,5-a]azepin-7-ol;

re/-(7Rf9R)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-9-(4-fluorophenyl)-7-methyl-6,7,8,9-tetrahydro-5H-[ 1 ,2,4]triazolo[l ,5-a]azepin-7-ol;

(7R,9S)-2-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenylamino)-9-(4-fluorophenyl)-7-methyl-6,7;8,9-tetrahydro-5H-[l52,4]triazolo[l,5-a]azepin-7-ol; (7Sf9S)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-9-(4-fluorophenyO^-methyl-όJ^^-tetrahydro-SH-tl^^JtriazolotUS-ajazepin-?^!; re/-(7R,9R)-2-(3-fluoro-4-(5-methyl- IH- 1 ,2,4-triazol- 1 -yl)phenylammo)-9-(4-fluorophenyl)-7-methyl~6?7,8,9-tetrahydro-5H-[l,2,4]lriazolo[l,5-a3azepin-7-ol; rel- (7 S ,9R)-2-(3 -fIuoro-4-(5 -methyl- 1 H- 1 ,2,4-triazol- 1 -y l)pheny lamino)-9-C4-fluorophenyl)-7-methyl-6,758,9-tetrahydro-5H-[l,2J43triazolo[l,5-a]azepin-7-ol; re/-(7R,9R)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-methyl"9-(4-(trifluoromethoxy)ρhenyl)-657,8 ,9-letrahydro-5H-[ 1 ;2,4]triazolo[ 1 ,5-a]azepin-7-ol; re/-(7S,9R)-2-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-methyl-9-(4-(trifluoromethoxy)phenyl)-6,7,8,9-letrahydro-5H-[l ,2s4]triazolo[l ,5-a]azepin-7-ol; rel- (7Rs9R)-2-(3-fluoro-4-(3-methyl-lH~l,2,4-lriazol-l-yl)phenylamino)-9-(4-fluorophenyl)-7-methyl-6,7,8,9-tetrahydro-5H-[l,2!4]triazolo[ls5-a]azepin-7-ol; re/-(7S,9R)-2-(3~fluoro-4-(3-methyl-lH-l,2,4-triazoI-l-yl)phenylamino)-9-
re/-(7Rf9R)-2-(3~fluoro-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenylamino)-9-(4-fluorophenyl)-6J7,8>9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-7-ol; re/-(7S,9R)-2-(3-fluoro-4-(5-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenylamino)-9-(4-fluorophenyl)-6,758,9-tetrahydro-5H-[l,2,4]triazolo[lϊ5-a]azepin-7-ol; N-(3-fluoro-4-(3 -methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-fluorophenyl)- 5,6,8,9-tetrahydrospiro[[l,2,4]triazolo[lJ5-a]azepine-7,2'-[l,3]dioxolan]-2-amine;

N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-fluorophenyl)-6,7,8 ,9-tetrahydro-5H-[l 52,4]triazolo[l ,5-a]azepin~2-amine;

N-(3 -fluoro-4-(5-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(3-fluoro-4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-(2J2-difluoroethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,2f4]triazolo[l?5-a]azepin-2-amine;

(S)-N-(4-(4-chloro- 1 H-imidazol- 1 -yl)-3 ~methoxyphenyl)-9-(4-(292-difluoroethoxy)phenyl)-6,7,8f9-tetrahydro-5H-[ 1 ,2,4]triazolo[l }5-a]azepin-2-amine;

(R)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-9-(4-(2?2-difluoroethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l;2,4]triazolo[l,5-a]azepin-2-amme; N-(3-fluoro-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-9-(3-fluoro-4- (trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l!2s4]triazoIo[l,5-a]azepin-2-amine;

(S)-N-(3-fluoro-4-(3-methyl-lH-l92,4-lriazol-l-yl)phenyl)-9-(3-fluoro-4" (trifluoromethoxy)phenyl)-6I7,8,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

(R)-N-(3-fluoro-4-(3-methyl-lH-l52,4-triazol-l-yl)phenyl)-9-(3-fluoro-4-(tπfluoromethoxy)phenyl)-6s758,9-tetrahydro-5H-[l,2,4]triazolo[l,5-a]azepin-2-amine;

N-(3-fluoro-5-methoxy-4-(3-methyl-l H- 1 ,2,4-triazoI- 1 -yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[l,254]triazolo[l,5-a]azepin-2-amine;

(S)-N-(3-fluoro-5-methoxy-4-(3-methyl- 1 H- 1 ,2,4-triazol-l -yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7?8 ,9-tetrahydro-5H- [ 1 ,2}4]triazolo [ 1 ,5 -a] azepin-2-aiTiine; (R)-N-(3-fiuoro-5-methoxy-4-(3-methyl- 1 H- 1 ,2,4-lriazol-l -yl)phenyl)-9-(4- (trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[ 1 S2,4]triazolo[l ,5-a]azepin-2-amine;

9-(4-bromophenyl)-N-(4-(4-chloro-l H-imidazol- 1 -yl)-3-methoxyphenyl)-6,7f8s9-tetrahydro-5H-[l ,2,4]triazolo[l ?5-a]azepin-2-amine; 9-(4-(lH-pyrazol-l-yl)phenyl)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-6,7,8f9-tetrahydro-5H-[l,2;)4]tπazolo[ls5-a]azepin-2-amine;

9-(4-(lH-l,254-triazol~l~yl)phenyl)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-6,75859-tetrahydro-5H-[l,2,43triazolo[lJ5-a]azepin-2-amine;

9-(4-(lH-imidazol-l-yl)phenyl)-N-(4-(4-chloro-lH-imidazol-l-yl)-3-methoxyphenyl)-6,7,8 ,9-tetrahydro-5H-[l ,2,4]triazolo[l >5-a]azepin-2-amine;

N-(4-(4-chloro-l H-imidazol- 1 -yl)-3-methoxyphenyl)-9-(4-(4-methyl- 1 H-pyrazol-1 -yl)phenyl)-6,7,8f9-tetrahydro-5H-f 1 ,254]triazolo[l s5-a]azepin-2-amine;

N-(2-fluoro-5-methoxy-4-(3-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-657s8s9-tetrahydro-5H-[l,2s4]triazolo[l,5-a]azepin-2-amine;

(S)-N-(2-fiuoro-5-methoxy-4-(3-methyl~lH-lf2,4-triazol-l-yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-5H-[ 1 ,2,4Jtriazolo[ 1 ,5-a]azepin-2-amine; and

(R)-N-(2-fluoro-5-melhoxy-4-(3-methyl- 1 H- 1 ,2,4-triazol- 1 -yl)phenyl)-9-(4-(trifluoromethoxy)phenyl)-6!7,8,9-tetrahydro-5H-[l>2s4]triazolo[l,5-a]azepin-2-amine; or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition for the treatment of disorders responsive to the reduction of β -amyloid peptide production comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier or diluent.

11. A method for the treatment of disorders responsive to the reduction of β-amyloid peptide production in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

12. A method of claim 11 wherein said disorder is selected from Alzheimer's Disease (AD), Down Syndrome, mild cognitive impairment (MCI), cerebral amyloid angiopathy (CAA), dementia with Lewy bodies (DLB), amyotrophic lateral sclerosis (ALS-D), inclusion body myositis (IBM), age-related macular degeneration, and cancer.

13. A method of claim 12 wherein said disorder is selected from Alzheimer's Disease and Down Syndrome.

14. A method of claim 13 wherein said disorder is Alzheimer's Disease.